Nevirapin Hexal (Nevirapine)

Nevirapine, the active ingredient in Nevirapin Hexal, is a Non‑nucleoside reverse transcriptase inhibitor (NNRTI) presented as a tablet for oral use. It treats HIV‑1 infection in adults and children.

GNH USA supplies Nevirapin Hexal as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Nevirapine is an antiretroviral drug that targets the HIV‑1 reverse transcriptase enzyme, forming part of combination therapy for HIV infection. - HIV‑1 infection: Reduces viral load and helps restore immune function. - Prevention of mother‑to‑child transmission of HIV: Lowers the risk of vertical transmission when used in appropriate regimens. - Combination antiretroviral therapy: Contributes to sustained viral suppression as a component of highly active antiretroviral therapy (HAART).

Nevirapine may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Rash: mild to moderate skin eruptions. - Nausea: occasional gastrointestinal discomfort. - Fatigue: generalized tiredness. - Headache: transient cranial pain.

Serious or Rare Side Effects: - Stevens‑Johnson syndrome: severe skin detachment requiring urgent care. - Hepatic failure: marked liver enzyme elevation or jaundice. - Hypersensitivity reactions: fever, eosinophilia, or multi‑organ involvement.

Nevirapine requires careful monitoring to minimise risks. - Liver function monitoring: check transaminases before and during therapy. - Rash surveillance: discontinue if severe or progressing. - Avoid potent CYP3A inducers: may reduce drug exposure. - Dose adjustment in hepatic impairment: follow prescriber guidance. - Contraindicated in patients with known hypersensitivity to nevirapine. - Store at below 25°C: keep in the original pack, protect from moisture.

Nevirapine interacts with several medicines that can alter its effectiveness or safety.

Major Interactions (Avoid): - Rifampicin: markedly reduces nevirapine concentrations. - St. John’s wort: induces metabolism, lowering exposure. - Carbamazepine: accelerates clearance, risking therapeutic failure.

Moderate Interactions (Monitor Closely): - Efavirenz: may increase hepatotoxic risk. - Protease inhibitors (e.g., ritonavir): can raise nevirapine levels. - Oral contraceptives: may have reduced efficacy, requiring additional contraception.